Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura

DOI Web Site PubMed 15 References

Bibliographic Information

Other Title
  • Rituximabが有効であった難治性特発性血小板減少性紫斑病
  • 臨床研究 Rituximabが有効であった難治性特発性血小板減少性紫斑病
  • リンショウ ケンキュウ Rituximab ガ ユウコウ デ アッタ ナンジセイ トクハツセイ ケッショウバン ゲンショウセイ シハンビョウ

Search this article

Abstract

A 75-year-old woman had an episode of sudden nasal and oral bleeding. After that, petechiae appeared on her entire body. She received a platelet transfusion, and was referred to our hospital. On admission, the platelet count was as low as 1.2×104/μl, and the PAIgG level was slightly elevated. Bone marrow cellularity was low, with a normal count of megakaryocytes. Anti-glycoprotein IIb/IIIa antibody-secreting B cells in the peripheral blood and platelet-associated anti-glycoprotein IIb/IIIa antibodies were significantly high, and the patient was diagnosed as having idiopathic thrombocytopenic purpura (ITP). She failed to respond to corticosteroids, splenectomy and other therapies, so we administered rituximab, anti-CD20 monoclonal antibody, 375 mg/m2 weekly for four weeks. After the second infusion of rituximab, the platelet count began to increase. The platelet count continued to rise until a peak count (15.0×104/μl) observed after 2 weeks from the fourth infusion, and the response was maintained for 8 more weeks. The levels of anti-glycoprotein IIb/IIIa antibody-secreting B cells and platelet-associated anti-glycoprotein IIb/IIIa antibodies decreased after the administration of rituximab. Rituximab was effective in this case of refractory ITP.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 45 (11), 1181-1186, 2004

    The Japanese Society of Hematology

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top